Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human erythropoietin in Friedreich's ataxia skeletal muscle biology study
2008-000040-13Phase 2Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Jan 2009
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epoetin beta in Friedreich ataxia (FA), sponsored by Medical University of Innsbruck. Primary endpoints: Baseline skeletal muscle morphology and biochemistry, Circulating progenitor cell response and 2 more. Started Jan 2009; status: completed.
02
Drugs
epoetin beta
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2008-000040-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000040-13.